Targets for anti-metastatic drug development

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Over 90% of cancer deaths result from metastasis, yet no anti-metastatic drugs are available.
• Tumor cell migration, essential for metastasis, is regulated by signaling molecules like chemokines, neurotransmitters, cytokines, and growth factors.
• Current oncology drug development primarily targets primary tumors, yielding limited success against metastatic disease.

Purpose of the Study:

• To review signaling molecules and their receptors that regulate tumor cell migration and metastasis.
• To identify potential anti-metastatic drug targets among agonists and antagonists of these receptors.
• To explore the repurposing of existing drugs, such as beta-blockers, for anti-metastatic therapy.

Main Methods:

• Literature review of signaling pathways involved in tumor cell migration and chemotaxis.
• Analysis of agonists and antagonists targeting G protein-coupled receptors and receptor kinases.
• Case study on the potential anti-metastatic application of beta-blockers.

Main Results:

• Key regulators of tumor cell migration include ligands for G protein-coupled receptors (chemokines, neurotransmitters) and receptor kinases (cytokines, growth factors).
• Numerous agonists and antagonists targeting these pathways show potential as anti-metastatic agents.
• Established drugs, exemplified by beta-blockers, may be repurposed to inhibit cancer cell metastasis.

Conclusions:

• Targeting the molecular regulators of tumor cell migration offers a promising strategy to combat cancer metastasis.
• Developing anti-metastatic drugs is crucial, given that metastasis accounts for the vast majority of cancer-related mortality.
• Repurposing existing drugs presents a viable avenue for developing novel anti-metastatic therapies.